DNLI Stock Cash Flow Statements

Denali Therapeutics Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Denali Therapeutics Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31

operating activities
net income	-124,119,000	-132,970,000	-114,753,000	-107,192,000	-99,026,000	-101,802,000	-119,473,000	-99,353,000	183,383,000	-109,781,000	-98,678,000	-103,299,000	-58,794,000	-65,220,000	-75,261,000	-84,588,000	-60,691,000	-70,041,000	244,885,000	-58,228,000	-58,758,000	-56,763,000	-54,025,000	-46,260,000	-58,337,000	-38,992,000	77,533,000	-35,371,000	-54,724,000	-23,678,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	3,045,000	2,325,000	1,853,000	1,838,000	1,942,000	2,162,000	2,177,000	2,217,000	2,285,000	10,047,000	4,091,000	2,141,000	2,072,000	2,079,000	2,094,000	2,187,000	2,204,000	2,108,000	2,121,000	2,156,000	2,145,000	2,109,000	2,055,000	1,890,000	1,643,000	2,403,000	2,379,000
stock–based compensation expense	25,387,000	25,160,000		24,860,000	25,100,000	27,840,000		27,460,000	26,570,000	28,084,000		24,579,000	23,936,000	26,145,000		20,998,000	21,136,000	21,028,000		13,252,000	12,484,000	10,785,000		8,901,000	13,714,000	6,874,000		5,510,000
net accretion of discounts on marketable securities	-2,697,000	-3,888,000	-6,165,000	-8,378,000
non-cash adjustment to operating lease expense	-1,112,000	-1,049,000	-1,049,000	-1,049,000	-1,019,000	-957,000	-957,000	-957,000	-928,000	-877,000	-863,000	-865,000	-840,000	-783,000	-783,000	-782,000	-728,000	-691,000	-691,000	-691,000
right-of-use asset amortization for finance lease	911,000	887,000	766,000
non-cash gain from divestiture of small molecule programs			0	0	0	-14,537,000
changes in operating assets and liabilities:
prepaid expenses and other current assets	24,957,000	-28,607,000
other non-current assets	3,965,000	-943,000	1,781,000
accounts payable	2,596,000	-2,639,000	1,286,000	-4,372,000	3,888,000	635,000	-2,081,000	-3,960,000	4,774,000	3,698,000	-1,715,000	1,902,000	839,000	1,248,000	-78,000	782,000	2,378,000	623,000	-1,770,000	891,000	-452,000	-292,000	567,000	-837,000	-662,000	1,965,000	-1,761,000	-5,859,000	8,045,000	-951,000
accruals and other current liabilities	-7,674,000	-6,477,000	11,287,000	14,246,000	-10,477,000	2,321,000	14,313,000	734,000	-32,209,000	19,810,000	4,027,000	9,332,000	5,865,000	-8,306,000	7,768,000	6,491,000	1,277,000	-10,804,000	17,226,000	7,095,000	1,612,000	-3,827,000
deferred research and development funding liability
net cash from operating activities	-75,298,000	-131,468,000	-83,715,000	-59,139,000	-91,220,000	-113,620,000	-98,657,000	-87,363,000	-113,169,000	-58,802,000	-72,663,000	-57,046,000	-42,898,000	-72,109,000	-65,494,000	-41,434,000	-54,221,000	-50,240,000	513,915,000	86,000	-43,357,000	-54,492,000	-47,643,000	-30,435,000	-43,175,000	-30,323,000	93,185,000	-34,822,000	-41,824,000	33,577,000
capex	-4,278,000	-5,078,000	-5,092,000	-3,884,000	-4,786,000	-2,150,000	-2,235,000	-2,068,000	-5,850,000	-2,786,000	-4,849,000	-6,050,000	-2,893,000	-4,041,000	-3,053,000	-1,875,000	-772,000	-2,800,000	-1,195,000	-706,000	-315,000	-879,000	0	-2,847,000	-10,271,000	-2,028,000	-1,437,000	-847,000	-572,000	-537,000
free cash flows	-79,576,000	-136,546,000	-88,807,000	-63,023,000	-96,006,000	-115,770,000	-100,892,000	-89,431,000	-119,019,000	-61,588,000	-77,512,000	-63,096,000	-45,791,000	-76,150,000	-68,547,000	-43,309,000	-54,993,000	-53,040,000	512,720,000	-620,000	-43,672,000	-55,371,000	-47,643,000	-33,282,000	-53,446,000	-32,351,000	91,748,000	-35,669,000	-42,396,000	33,040,000
investing activities
purchases of marketable securities	0	-137,926,000	-173,701,000	-100,461,000	-121,645,000	-834,157,000	-413,718,000	-498,141,000	-378,127,000	-523,714,000	-486,710,000	-122,870,000	-141,123,000	-364,337,000	-231,447,000	-344,195,000	-384,191,000	-463,105,000	-597,945,000	-363,916,000	-170,452,000	-153,155,000		-75,110,000	-34,219,000	-109,810,000
maturities and sales of marketable securities	162,213,000	161,752,000		198,000,000	225,000,000	383,120,000	489,000,000	601,118,000	552,044,000	433,785,000	364,000,000	144,339,000	232,647,000	250,500,000	193,750,000	293,062,000	482,500,000	440,500,000	231,800,000	152,500,000	140,356,000	140,701,000				103,791,000	97,327,000	84,525,000	64,750,000	27,299,000
purchases of property and equipment	-4,278,000	-5,078,000	-5,092,000	-3,884,000	-4,786,000	-2,150,000	-2,235,000	-2,068,000	-5,850,000	-2,786,000	-4,849,000	-6,050,000	-2,893,000	-4,041,000	-3,053,000	-1,875,000	-772,000	-2,800,000	-1,195,000	-706,000	-315,000	-879,000		-2,847,000	-10,271,000	-2,028,000
net cash from investing activities	157,935,000	18,748,000	172,207,000	93,655,000	98,569,000	-453,187,000	73,047,000	100,909,000	168,067,000	-92,715,000	-127,559,000	15,419,000	88,631,000	-117,878,000	-40,750,000	-53,008,000	97,537,000	-25,405,000	-367,340,000	-212,122,000	-30,411,000	-13,333,000	42,385,000	49,493,000	63,881,000	-8,047,000	-61,403,000	44,727,000	30,528,000	-301,274,000
financing activities
proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of 480
proceeds from exercise of awards under equity incentive plans	4,057,000	595,000	4,155,000	5,456,000	6,756,000	1,022,000	4,705,000	2,492,000	9,019,000	1,604,000	3,436,000	5,154,000	4,402,000	1,463,000	5,168,000	3,315,000	7,043,000	3,822,000	9,522,000	5,753,000	3,415,000	1,965,000	2,034,000	679,000	2,569,000	908,000		658,000
payments for finance lease right-of-use asset	-2,434,000	-4,357,000	-8,323,000
net cash from financing activities	1,623,000	-3,762,000	-4,168,000	-18,559,000	6,756,000	500,275,000	4,705,000	2,492,000	9,019,000	1,604,000	299,651,000	5,154,000	4,402,000	1,463,000	5,168,000	3,315,000	7,043,000	3,822,000	9,522,000	425,899,000	3,415,000	195,913,000	2,034,000	679,000	2,569,000	908,000	1,690,000	658,000	1,432,000	93,239,000
net decrease in cash, cash equivalents and restricted cash	84,260,000	-116,482,000		15,957,000	14,105,000	-66,532,000	-20,905,000	16,038,000	63,917,000	-149,913,000		-36,473,000	50,135,000	-188,524,000											23,275,000	-37,462,000				-174,458,000
cash, cash equivalents and restricted cash at beginning of period	0	176,535,000		0	0	128,681,000		0	0	219,544,000		0	0	294,977,000		0	0	508,644,000		0	0	80,949,000		0	0	78,623,000		0	0	218,910,000
cash, cash equivalents and restricted cash at end of period	84,260,000	60,053,000		15,957,000	14,105,000	62,149,000		16,038,000	63,917,000	69,631,000		-36,473,000	50,135,000	106,453,000		-91,127,000	50,359,000	436,821,000		213,863,000	-70,353,000	209,037,000		19,737,000	23,275,000	41,161,000		10,563,000	-9,864,000	44,452,000
supplemental disclosures of cash flow information
equity consideration received in the divestiture of small molecule programs			0	0	0	15,000,000
deferred research and development funding liability, less current portion		16,733,000
right-of-use asset obtained in exchange for new finance lease liabilities		2,876,000
cash paid for finance lease interest		181,000	181,000
property and equipment purchases accrued but not yet paid		488,000	929,000	35,000	-1,719,000	1,947,000	-5,677,000	5,655,000	-5,500,000	6,075,000	1,180,000	-37,000	207,000	114,000	564,000	-200,000			35,000	30,000				-662,000	593,000	1,569,000	298,000			246,000
issuance costs incurred but not yet paid						394,000
stock-based compensation expense																														2,925,000
other non-cash items											12,000	46,000						-2,000	20,000	57,000	14,000	-53,000	76,000	-114,000
prepaid expenses and other assets					-1,570,000	-18,766,000	-6,004,000	87,000	3,612,000	-1,789,000	-1,374,000	13,365,000	-15,993,000	1,242,000	-20,914,000	16,104,000	-14,356,000	6,301,000	-14,388,000	25,000	6,248,000	-2,454,000	863,000	3,108,000	-145,000	2,849,000	-12,911,000	-3,661,000	-105,000	-1,613,000
contract liabilities											-23,000	-3,375,000	0	-27,915,000	-1,324,000	-4,426,000	-7,144,000	969,000	-1,333,000	-9,276,000	-5,575,000	-3,069,000		-1,181,000	-839,000	-777,000
related party contract liability														-2,226,000	-1,191,000	-860,000	-794,000	-892,000	252,564,000
other non-current liabilities
maturities of marketable securities																								127,450,000
proceeds from public offering of common stock, net of issuance costs																			0	0	0	193,948,000
net increase in cash, cash equivalents and restricted cash															-101,076,000	-91,127,000	50,359,000	-71,823,000	156,097,000	213,863,000	-70,353,000	128,088,000	-3,224,000
cash, cash equivalents and restricted cash at beginning of year
cash, cash equivalents and restricted cash at end of year
increase in right-of-use asset due to lessor assets			0
cash paid during the year for income taxes
related-party contract liability								-1,268,000	-289,123,000	-141,000		-184,000
proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of 480k				0	0	499,253,000
non-cash recognition of new finance lease
cash paid during the period for income taxes								0	0	4,000
net amortization of premiums and (discounts) on marketable securities						-10,516,000	-12,243,000	-12,323,000	-11,533,000	-7,853,000																-1,317,000
proceeds from issuance of common stock in connection with collaboration agreements
net amortization of premiums on marketable securities												-688,000	491,000	1,627,000
tenant improvements provided by the landlord																							0	2,000	0	11,341,000	10,197,000
net amortization of premiums (discounts) on marketable securities
net amortization of discounts on marketable securities																	2,495,000	1,161,000		-49,000	-418,000	-607,000		-1,298,000
deferred rent																											4,620,000	157,000	-1,114,000	-225,000
payments of issuance costs related to issuance for common stock																											0	0
payments of issuance costs related to issuance for preferred stock																											0	0
proceeds from issuance of common stock in connection with the biogen stock purchase agreement
non-cash operating lease expense																						321,000
operating lease liability																						-642,000
net amortization of (discounts) and premiums on marketable securities
accrued and other current liabilities																							-1,376,000	4,763,000	2,706,000	-4,593,000	6,474,000	4,042,000	1,854,000	-3,257,000
contract liability																											11,667,000	-1,195,000	-1,648,000	59,953,000
purchase of marketable securities																											-157,293,000	-38,951,000	-33,650,000	-328,036,000
purchase of property and equipment																											-1,437,000	-847,000	-572,000	-537,000
issuance of common stock in connection with the takeda collaboration agreement
proceeds from issuance of common stock, net of issuance costs
proceeds from issuance of convertible preferred stock, net of issuance costs
deferred ipo costs incurred but not yet paid
convertible preferred stock issuance costs incurred but not yet paid
non-cash rent expense																								593,000	475,000	1,265,000
gain on disposal of property and equipment																												0	8,000	-44,000
payments of issuance costs related to issuance of common stock																														-1,342,000
payments of issuance costs related to issuance of preferred stock																														-44,000
(gain) loss on disposal of property and equipment
fair value of common stock issued in connection with asset acquisition
purchase of other investments
proceeds from exercise of common stock options																														219,000
net increase in cash and cash equivalents
net amortization of premiums and discounts on marketable securities																												-772,000	-705,000	-387,000
issuance of common stock in connection with collaboration agreement																												0	0	94,406,000
deferred ipo costs accrued but not yet paid
depreciation																													1,855,000	854,000
cash from operating activities
cash from investing activities
cash from financing activities

We provide you with 20 years of cash flow statements for Denali Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Denali Therapeutics stock. Explore the full financial landscape of Denali Therapeutics stock with our expertly curated income statements.

The information provided in this report about Denali Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.